Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal
Lead Drug Felzartamab Is Pipeline-In-A-Product
Executive Summary
Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab.